Autres langues OncoCyte Corporation

Actions

OCX

US68235C2061

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 19/04/2024			Varia. 5j.	Varia. 1 janv.
2,5 ^USD	-2,34 %		-7,75 %	0,00 %

16/04	Broadwood Capital, Inc. s'engage avec OncoCyte Corporation	CI
12/04	Le secteur des soins de santé est stable avant la cloche vendredi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Broadwood Capital, Inc. Engages with OncoCyte Corporation	16/04
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS	15/04
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules	15/04
Sector Update: Health Care Stocks Steady Pre-Bell Friday	12/04
Oncocyte Reports Full Year 2023 Financial Results	12/04
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	12/04
OncoCyte Agrees to $15.8 Million Private Placement of Stock, Warrants	12/04
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules	12/04
Oncocyte : and Bio-Rad Partner on Global Launch of Transplant Assay - Form 8-K	11/04
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay	11/04
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	11/04
OncoCyte Corporation announced that it expects to receive $15.8 million in funding	11/04
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results	09/04
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico	16/01
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays	06/12
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays	06/12
OncoCyte: Q3 Earnings Snapshot	09/11
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Oncocyte Reports Third Quarter 2023 Financial Results	09/11
Oncocyte to Announce Third Quarter 2023 Financial Results	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues OncoCyte Corporation

Actions

OCX

US68235C2061

Autres langues

Filtres